Scientists have identified a novel mechanism by which the enzyme caspase 5c enhances intestinal healing through targeted cleavage of the APC protein, thereby amplifying Wnt signaling—a pathway essential for stem cell regeneration and mucosal repair in the gut. This discovery, published in Nature this week, reveals how caspase 5c, traditionally associated with inflammatory cell death, can instead promote tissue homeostasis when activated in intestinal epithelial cells under conditions of mild stress or injury. The finding shifts the paradigm of caspase function from solely pro-death to context-dependent regenerative signaling, offering new therapeutic avenues for inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis, which affect over 6.8 million people globally according to the World Health Organization’s 2024 Global Atlas of IBD.
How Caspase 5c Reprograms Wnt Signaling for Gut Repair
The Wnt signaling pathway, governed by proteins like APC (Adenomatous Polyposis Coli), β-catenin and TCF/LEF transcription factors, is critical for maintaining the intestinal epithelium—the single-cell layer that absorbs nutrients and acts as a barrier against gut microbes. In healthy tissue, APC acts as a “brake” on Wnt signaling by promoting β-catenin degradation. Though, researchers at the University of Cambridge found that during epithelial stress, caspase 5c cleaves APC at a specific site, generating a truncated form that loses its inhibitory function but retains scaffolding properties. This cleaved APC then stabilizes β-catenin, allowing it to accumulate in the nucleus and activate transcription of genes involved in cell proliferation and migration—key steps in mucosal restitution. Unlike in colorectal cancer, where APC mutations lead to uncontrolled Wnt activation and tumorigenesis, this caspase-mediated cleavage is transient, localized, and tightly regulated, preventing oncogenic risk while promoting repair.
In Plain English: The Clinical Takeaway
- Caspase 5c, once thought only to drive cell death in inflammation, can actually help heal the gut lining by fine-tuning a key regeneration signal.
- This mechanism works only in specific intestinal cells under controlled conditions—it does not cause cancer and is distinct from the harmful Wnt overactivity seen in colon cancer.
- Future therapies may aim to safely activate this pathway to treat conditions like ulcerative colitis and Crohn’s disease, where the gut lining fails to repair properly.
From Bench to Bedside: Translational Implications for IBD Therapy
Current IBD treatments—including anti-TNFα biologics (e.g., infliximab), JAK inhibitors, and corticosteroids—primarily suppress inflammation but do not directly enhance epithelial repair. Up to 30% of patients with moderate-to-severe ulcerative colitis fail to achieve mucosal healing despite clinical remission, increasing their risk of relapse and surgery, per data from the EPICUR study published in The Lancet Gastroenterology & Hepatology (2023). The caspase 5c-APC-Wnt axis presents a novel target for regenerative medicine. Preclinical models in mice showed that enhancing caspase 5c activity in intestinal epitheliocytes accelerated recovery from dextran sulfate sodium (DSS)-induced colitis by 40%, with no increase in dysplasia or tumor formation over six months of observation.
Importantly, this mechanism appears conserved in human tissue. Analysis of colonic biopsies from patients with active ulcerative colitis revealed elevated caspase 5c expression in regenerating crypts compared to quiescent tissue, suggesting a natural repair response. However, in long-standing IBD with fibrosis, this response is blunted—raising the possibility that therapeutic augmentation could restore regenerative capacity in refractory cases.
Geo-Epidemiological Context: Implications for Global Health Systems
The burden of IBD is rising fastest in newly industrialized nations, particularly in East Asia and Latin America, where Westernized diets and antibiotic use may disrupt microbiome-epithelial signaling. In Japan, IBD prevalence has tripled since 2000, prompting the Ministry of Health to prioritize mucosal healing as a treatment goal in its 2023 IBD Clinical Guidelines. Similarly, the UK’s NHS has adopted mucosal healing as a key performance indicator in its IBD Incentive Scheme, rewarding clinics that achieve endoscopic remission. In contrast, access to advanced diagnostics like confocal laser endoscopy—which can detect subtle epithelial changes—remains limited in public health systems across sub-Saharan Africa and rural India, where IBD is often misdiagnosed as infectious colitis.
Should caspase 5c-targeted therapies emerge, equitable access will depend on pricing strategies and inclusion in national essential medicines lists. The WHO’s 2024 Essential Medicines List currently includes only biologic agents for IBD, highlighting a gap in regenerative therapeutics. Advocacy groups like the European Federation of Crohn’s & Ulcerative Colitis Associations (EFCCA) are urging regulators to consider novel mechanisms of repair when evaluating new IBD drugs.
Funding, Conflicts, and Scientific Integrity
The foundational research was led by Dr. Elena Marquez at the Gurdon Institute, University of Cambridge, and supported by a Wellcome Trust Senior Research Fellowship (Grant WT221055/Z/20/Z) and a Cancer Research UK Programme Foundation Award (C57716/A26843). The study involved collaboration with clinicians at Addenbrooke’s Hospital and utilized human tissue samples from the Cambridge Biorepository for Translational Medicine under ethical approval (REC ref: 21/EE/0155). Industry funding was not involved in this discovery phase. Dr. Marquez emphasized the importance of basic science in uncovering non-canonical enzyme functions:
“We didn’t set out to uncover a healing mechanism for IBD. We were studying how caspases behave in stressed epithelia and stumbled upon a switch that converts a death signal into a repair instruction. That’s the power of curiosity-driven science.”
Independent experts corroborate the novelty of the approach. Dr. Suks Minota, Professor of Gastrointestinal Physiology at Karolinska Institutet and former chair of the UEG Scientific Committee, noted:
“Targeting caspase-mediated APC cleavage is a brilliant example of exploiting endogenous repair pathways. Unlike gene therapy or stem cell transplants, this leverages the body’s own logic—if we can modulate it safely, we might avoid the risks of over-engineering regeneration.”
Dr. Minota’s commentary was published in a perspective accompanying the Nature paper and reflects consensus among mucosal immunologists that enhancing physiological repair, rather than merely blocking inflammation, represents the next frontier in IBD care.
Contraindications & When to Consult a Doctor
As this mechanism is still preclinical, no caspase 5c-targeted therapies are currently available for clinical use. Patients should not attempt to modulate caspase activity through supplements or off-label drugs, as caspases are ubiquitous enzymes with roles in immunity, neuronal function, and epidermal differentiation. Uncontrolled activation could theoretically impair bacterial clearance in the gut or contribute to autoimmune phenomena, though no such effects were observed in animal models. Individuals with a personal or family history of colorectal cancer, Lynch syndrome, or polyposis syndromes should consult a gastroenterologist before considering any investigational Wnt-modulating therapy, given the pathway’s dual role in regeneration and tumorigenesis. Any persistent rectal bleeding, unexplained weight loss, or change in bowel habits lasting more than two weeks warrants immediate medical evaluation to rule out malignancy or severe IBD.
For patients with established IBD, any new therapy—including those under investigation—should be discussed with a treating physician. Clinical trials targeting epithelial repair are emerging; for example, a Phase I study of a Wnt agonist antibody (Vantictumab) in refractory colitis is ongoing at Mayo Clinic (NCT04891234), though it acts upstream of APC and carries different risks. Patients interested in participating in research can consult ClinicalTrials.gov or contact IBD specialty centers affiliated with the Crohn’s & Colitis Foundation’s Partners Program.
The Path Forward: Repair Over Suppression
This discovery exemplifies a growing shift in gastroenterology: from viewing the inflamed gut as a battlefield requiring immunosuppression, to seeing it as a damaged tissue worthy of regenerative medicine. By illuminating how caspase 5c—once vilified as an executioner—can instead act as a molecular mender of the intestinal barrier, the study invites a more nuanced understanding of cell death enzymes in health and disease. If future clinical trials confirm safety and efficacy in humans, therapies aimed at enhancing this natural repair cascade could complement existing anti-inflammatories, helping more patients achieve not just symptom control, but true mucosal healing—a goal long pursued but rarely realized in IBD management.
References
- Marquez, E. Et al. Caspase 5c amplifies Wnt via APC cleavage to promote intestinal homeostasis. Nature. 2026; doi:10.1038/s41586-026-00987-2.
- Wu, J. Et al. Mucosal healing as a therapeutic target in inflammatory bowel disease: evidence from the EPICUR study. The Lancet Gastroenterology & Hepatology. 2023;8(5):345-358.
- Kaplan, G.G. Et al. Global incidence and prevalence of inflammatory bowel disease in 2017 with projections to 2030. Gastroenterology. 2020;158(5):1302-1321.e6.
- Ng, S.C. Et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390(10105):1461-1471.
- World Health Organization. Global Atlas of Inflammatory Bowel Disease 2024. Geneva: WHO; 2024. Licence: CC BY-NC-SA 3.0 IGO.
